Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

Not Applicable

Completed

• Conditions: Breast Cancer

• Registration Number: NCT02101970
• Lead Sponsor: Carol Fabian, MD

Brief Summary

The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.

Detailed Description

Subjects will all participate in a 6-month weight loss intervention. Subjects will be randomized to receive either blinded placebo or omega-3 fatty acids for 6 months.

Study Timeline

• Study Start: 2014-03
• Study First Submitted: 2014-03-28
• Study First Submitted QC: 2014-03-28
• Study First Posted: 2014-04-02
• Primary Completion: 2016-05
• Study Completion: 2018-08-27
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-06
• Last Update Posted: 2022-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 46

Inclusion Criteria

• Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA)
• Access to smart phone and or computer
• Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase.
• Willing to start the dietary and exercise intervention within 9 months of RPFNA
• Willing to complete quality of life questionnaires at multiple visits
• Willing to have a medical history and physical at multiple visits
• Willing to have an additional RPFNA at two additional visits
• Be willing to have blood drawn at multiple visits
• Willing to sign and able to understand consent for the RPFNA's and study participation
• Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial.

Exclusion Criteria

• Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration
• Have changed dose or type of hormone supplementation within 3 months
• Currently receiving other investigational agents
• Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months.
• Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents
• Taking metformin, or other diabetes medications
• Taking statins
• Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics)
• Would be unable to participate, by phone, in weekly phone call sessions
• Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Dropout rate	Up to 6 Months	Measured as the number of participants that dropout before diet+intervention period is complete

Secondary Outcome Measures

Name	Time	Method
Modulation of breast cancer risk biomarkers	Change from Baseline to 12 Months	Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers
Modulation of breast cancer risk biomarkers in benign breast tissue	Change from Baseline to 12 Months	Measure change in fasting and postprandial blood inflammatory, and risk biomarkers
Weight gain	Change from 6 Months to 12 Months	Measure change in weight in participants during the 6-12 month maintenance phase
Study design feasibility	Up to 6 months	Based on eligibility criteria, study procedures and participation of subjects the study design will be measured to see if it will practically work with a larger study population
Change in Gut Microbiome	Change from Baseline to Month 6	Change in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA):arachidonic acid (AA) ratio

Trial Locations

Locations (1)

University of Kansas Medical Center, Breast Cancer Prevention Center; 🇺🇸 Kansas City, Kansas, United States